Laurence Gorlick
Internal Medicine · Rolling Hills Estates, CANPI 1669411542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 284 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 29.0% of the total. Reporting peaked in 2021 at $1,742 and has fallen 98.7% since, to $22 in 2023. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$686
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$346
- Takeda Pharmaceuticals U.S.A., Inc.$343
- GSK$263
- Johnson & Johnson$178
- plus $1K from 29 others
What the payments were for
- Consulting fees$251%
- Food & beverage$4,43798%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,307 |
| AstraZeneca | 38 | $686 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $343 |
| GSK | 16 | $263 |
| Johnson & Johnson | 6 | $178 |
| Pfizer | 6 | $141 |
| Avanir Pharmaceuticals, Inc. | 18 | $109 |
| Amgen | 6 | $106 |
| Novo Nordisk | 5 | $97 |
| Lilly USA, LLC | 5 | $93 |
| Arbor Pharmaceuticals, Inc. | 6 | $92 |
| Bayer | 5 | $73 |
| Amarin Pharma, Inc. | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Merck | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Neos Therapeutics, LP | 3 | $46 |
| Genentech USA, Inc. | 2 | $45 |
| LEO Pharma Inc. | 2 | $43 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Corium, LLC | 2 | $37 |
| Almatica Pharma LLC | 2 | $30 |
| Cranial Technologies, Inc | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Gilead | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Kaleo, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$4,510 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $2,275 |
| Doxepin Hcl | 15 | $692 |
| Rosuvastatin Calcium | 25 | $488 |
| Mirtazapine | 17 | $339 |
| Clonazepam | 12 | $172 |
| Sumatriptan Succinate | 12 | $127 |
| Lorazepam | 17 | $77 |
| Carisoprodol | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rolling Hills Estates
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.